Health-related quality of life in patients with recurrent Clostridioides difficile infections

Lianna H Hammeken, Simon M D Baunwall, Jens F Dahlerup, Christian L Hvas, Lars H Ehlers, Lianna H Hammeken, Simon M D Baunwall, Jens F Dahlerup, Christian L Hvas, Lars H Ehlers

Abstract

Background: The health-related quality of life (HrQoL) can be substantially affected in patients with recurrent Clostridioides difficile infection (rCDI) but the impact of effective treatment of the infection remains unclear. This study aimed to evaluate the HrQoL in patients with rCDI and estimate the gain in HrQoL associated with effective treatment of rCDI.

Methods: Patients' HrQoL was estimated based on EuroQol 5-Dimensions 3-Levels (EQ-5D-3L) questionnaires obtained from a Danish randomised controlled trial (RCT). In the RCT, 64 patients with rCDI were randomised to receive either vancomycin (n = 16), fidaxomicin (n = 24) or faecal microbiota transplantation (FMT) preceded by vancomycin (n = 24). The primary outcome in the RCT was rCDI resolution. Patients were closely monitored during the RCT, and rescue FMT was offered to those who failed their primary treatment. Patients' HrQoL was measured at baseline and at 8- and 26-weeks follow-up. Linear regression analyses conditional on the differences between baseline and follow-up measurements were used to assess statistical significance (p < 0.05).

Results: Within 26 weeks of follow-up, 13 (81%) patients treated with vancomycin, 12 (50%) patients treated with fidaxomicin, and 3 (13%) patients treated with FMT had a subsequent recurrence and received a rescue FMT. The average HrQoL for untreated patients with rCDI was 0.675. After receiving effective treatment, this value increased by 0.139 to 0.813 (p < 0.001) at week 8 and by 0.098 to 0.773 (p = 0.003) at week 26 of follow-up compared with baseline.

Conclusion: The HrQoL was adversely affected in patients with an active episode of rCDI but increased substantially after receiving an effective treatment algorithm in which rescue FMT was provided in case of a primary treatment failure.

Trial registration: The RCT was preregistered at EudraCT (j.no. 2015-003004-24, https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003004-24/results) and at ClinicalTrials.gov (study identifier NCT02743234, https://ichgcp.net/clinical-trials-registry/NCT02743234).

Keywords: clostridioides difficile; fecal microbiota transplantation; health-related quality of life.

Conflict of interest statement

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

© The Author(s), 2022.

References

    1. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372: 1539–1548.
    1. Napolitano LM, Edmiston CE, Jr. Clostridium difficile disease: diagnosis, pathogenesis, and treatment update. Surgery 2017; 162: 325–348.
    1. Magill SS, Edwards JR, Bamberg W, et al.. Multistate point-prevalence survey of health care-associated infections. N Eng J Med 2014; 370: 1198–1208.
    1. Kuipers EJ, Surawicz CM. Clostridium difficile infection. Lancet 2008; 371: 1486–1488.
    1. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769–1775.
    1. Louie TJ, Miller MA, Mullane KM, et al.. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Eng J Med 2011; 364: 422–431.
    1. Lee C, Louie TJ, Weiss K, et al.. Fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: Canadian outcomes. Can J Infect Dis Med Microbiol 2016; 2016: 8048757.
    1. Baunwall SMD, Lee MM, Eriksen MK, et al.. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. EClinicalMedicine 2020; 29–30: 100642.
    1. Garey KW, Aitken SL, Gschwind L, et al.. Development and validation of a Clostridium difficile health-related quality-of-life questionnaire. J Clin Gastroenterol 2016; 50: 631–637.
    1. Lurienne L, Bandinelli PA, Galvain T, et al.. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes 2020; 4: 14.
    1. Guillemin I, Marrel A, Lambert J, et al.. Patients’ experience and perception of hospital-treated Clostridium difficile infections: a qualitative study. Patient 2014; 7: 97–105.
    1. Vergel YB, Sculpher M. Quality-adjusted life years. Pract Neurol 2008; 8: 175–182.
    1. Haraldstad K, Wahl A, Andenæs R, et al.. A systematic review of quality of life research in medicine and health sciences. Qual Life Res 2019; 28: 2641–2650.
    1. Brazier J, Ara R, Azzabi I, et al.. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health 2019; 22: 267–275.
    1. Drummond MF, Sculpher MJ, Claxton K, et al.. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press, 2015.
    1. Wilcox MH, Ahir H, Coia JE, et al.. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. J Antimicrob Chemother 2017; 72: 2647–2656.
    1. Barbut F, Galperine T, Vanhems P, et al.. Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes 2019; 17: 6.
    1. Heinrich K, Harnett J, Vietri J, et al.. Impaired quality of life, work, and activities among adults with Clostridium difficile infection: a multinational survey. Dig Dis Sci 2018; 63: 2864–2873.
    1. Le P, Nghiem VT, Mullen PD, et al.. Cost-effectiveness of competing treatment strategies for Clostridium difficile infection: a systematic review. Infect Control Hosp Epidemiol 2018; 39: 412–424.
    1. Hammeken LH, Baunwall SMD, Hvas CL, et al.. Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review. Health Econ Rev 2021; 11: 3.
    1. Hvas CL, Dahl Jørgensen SM, Jørgensen SP, et al.. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology 2019; 156: 1324–1332.
    1. Jørgensen SMD, Erikstrup C, Dinh KM, et al.. Recruitment of feces donors among blood donors: results from an observational cohort study. Gut Microbes 2018; 9: 540–550.
    1. EuroQol Research Foundation. EQ-5D-3L user guide, (2018, accessed 12 April 2021).
    1. Wittrup-Jensen KU, Lauridsen J, Gudex C, et al.. Generation of a Danish TTO value set for EQ-5D health states. Scand J Public Health 2009; 37: 459–466.
    1. Faria R, Gomes M, Epstein D, et al.. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics 2014; 32: 1157–1170.
    1. National Research Council. Panel on Handling Missing Data in Clinical Trials: Committee on National Statistics Division of Behavioral and Social Sciences and Education. The prevention and treatment of missing data in clinical trials. Washington, DC: The National Academies Press, 2010.
    1. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011; 30: 377–399.
    1. The North Denmark Region. Hvordan har du det? Sundhedsprofil for Nordjylland 2017 [How are you? Health profile for the North Denmark Region 2017], (2018, accessed 12 April 2021).
    1. Van Nood E, Vrieze A, Nieuwdorp M, et al.. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407–415.
    1. Cammarota G, Masucci L, Ianiro G, et al.. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41: 835–843.
    1. Johnson S, Lavergne V, Skinner AM, et al.. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on Management of Clostridioides difficile infection in adults. Clin Infect Dis 2021; 73: e1029–e1044.
    1. Baunwall SMD, Dahlerup JF, Engberg JH, et al.. Danish national guideline for the treatment of Clostridioides difficile infection and use of faecal microbiota transplantation (FMT). Scand J Gastroenterol 2021; 56: 1056–1077.
    1. Brazier J, Roberts J, Tsuchiya A, et al.. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004; 13: 873–884.
    1. Lien K, Tam VC, Ko YJ, et al.. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer. Curr Oncol 2015; 22: e443–e452.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅